RecruitingPhase 1NCT07077434

A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors

A Phase 1 Open-Label, Multi-Center Study to Evaluate Pharmacokinetics, Safety and Tolerability of Navlimetostat (BMS-986504) in Japanese and Chinese Participants With Advanced Solid Tumors With Homozygous MTAP Deletion

Sponsor

Bristol-Myers Squibb

Enrollment

32 participants

Start Date

Oct 15, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

The purpose of this study is to evaluate the safety, tolerability and drug levels of Navlimetostat (BMS-986504) in participants with advanced solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BMS-986504 for people with advanced solid tumors. The study is currently recruiting participants at 12 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBMS-986504

Specified dose on specified days

Locations(12)

Beijing Cancer hospital

Beijing, Beijing Municipality, China

Fujian Cancer Hospital

Fuzhou, Fujian, China

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

Peking University Shenzhen Hospital

Shenzhen, Guangdong, China

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

The First Affiliated Hospital of Xinxiang Medical University

Xinxiang, Henan, China

Shandong Cancer Hospital

Jinan, Shandong, China

Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China

Kanagawa cancer center

Yokohama, Kanagawa, Japan

Shizuoka Cancer Center

Sunto-gun, Shizuoka, Japan

National Cancer Center Hospital

Chuo-ku, Tokyo, Japan

The Cancer Institute Hospital of JFCR

Koto-ku, Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07077434

Related Trials

A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

NCT070609892 locations

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT042224132 locations

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

NCT0585336725 locations

A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours.

NCT076484721 location

Study of CM518D1 in Patients With Advanced Solid Tumors

NCT070197791 location